Make assignment on pituitary gland and thyroid gland for pharmacy student
Asking for Preferences
What format do you want the assignment in? · What level of detail should the assignment cover?
Reading File
Finding Sources
Finding Sources
Good, I have key sources. Let me now read content from the most relevant textbooks in parallel — Robbins (pathology), Goodman & Gilman (pharmacology), and Guyton (physiology) for pituitary; and Robbins + Goodman & Gilman for thyroid.
Reading File
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
Reading File
Finding Sources
I now have rich material from Robbins, Goodman & Gilman, and Guyton. Let me read one more key section — antithyroid drug details — and then compile the full assignment.
Reading File
I now have sufficient material to write the complete assignment. Let me compile it.Here is the complete assignment:
ASSIGNMENT: PITUITARY GLAND AND THYROID GLAND
For Pharmacy Students — Endocrine Pharmacology
PART 1: THE PITUITARY GLAND
1.1 Anatomy and Structure
The pituitary gland is a small, bean-shaped structure located at the base of the brain within the sella turcica (a bony cavity in the sphenoid bone). It is connected to the hypothalamus by a stalk that carries both nerve axons and a rich venous plexus called the hypophyseal portal system. The gland has a central role in coordinating endocrine function across the body, acting as the "master gland."
The pituitary is divided into two morphologically and functionally distinct lobes:
Anterior Lobe (Adenohypophysis) — accounts for approximately 80% of the gland mass. It is composed of epithelial cells derived embryologically from the developing oral cavity (Rathke's pouch). In histological sections, three cell types are visible:
- Acidophils — eosinophilic cytoplasm; produce GH and prolactin
- Basophils — basophilic cytoplasm; produce TSH, ACTH, FSH, LH
- Chromophobes — poorly staining; reserve or degranulated cells
Posterior Lobe (Neurohypophysis) — composed mainly of glial-like supporting cells called pituicytes and terminal nerve endings of axons originating from the supraoptic and paraventricular nuclei of the hypothalamus. It does not synthesize hormones; it stores and releases hormones made in the hypothalamus.
— Robbins, Cotran & Kumar: Pathologic Basis of Disease
1.2 Cell Types of the Anterior Pituitary
There are six terminally differentiated cell types, each producing specific hormones:
| Cell Type | Hormone Produced |
|---|---|
| Somatotrophs | Growth Hormone (GH) |
| Mammosomatotrophs | GH and Prolactin (PRL) |
| Lactotrophs | Prolactin (PRL) |
| Corticotrophs | Adrenocorticotropic Hormone (ACTH) |
| Thyrotrophs | Thyroid-Stimulating Hormone (TSH) |
| Gonadotrophs | Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH) |
The differentiation of these cells is regulated by transcription factors during embryogenesis. For example:
- Somatotrophs, lactotrophs, and thyrotrophs share a common precursor expressing transcription factor POU1F1 (PIT-1)
- Corticotrophs arise from progenitors expressing TPIT (Tbx19)
- Gonadotrophs arise from progenitors expressing SF-1 and GATA-2
— Robbins, Cotran & Kumar: Pathologic Basis of Disease
1.3 Hypothalamic–Pituitary Axis
The release of anterior pituitary hormones is controlled by hypothalamic releasing and inhibiting factors carried through the hypophyseal portal venous plexus. The most clinically important are:
| Hypothalamic Factor | Effect on Pituitary |
|---|---|
| Growth Hormone-Releasing Hormone (GHRH) | Stimulates GH release |
| Somatostatin | Inhibits GH (and TSH) release |
| Thyrotropin-Releasing Hormone (TRH) | Stimulates TSH (and PRL) release |
| Corticotropin-Releasing Hormone (CRH) | Stimulates ACTH release |
| Gonadotropin-Releasing Hormone (GnRH) | Stimulates FSH and LH release |
| Dopamine | Inhibits prolactin release |
1.4 Posterior Pituitary Hormones
The posterior pituitary releases two peptide hormones, both nonapeptides (9 amino acids):
Antidiuretic Hormone (ADH / Vasopressin)
- Synthesized primarily in the supraoptic nuclei of the hypothalamus
- Amino acid sequence: Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-GlyNH₂
- Function: Acts on renal collecting tubules and ducts → increases water reabsorption → decreases urine output (antidiuresis). As little as 2 nanograms can elicit antidiuresis.
- In the absence of ADH, collecting tubules become almost completely impermeable to water → large volumes of dilute urine are produced (diabetes insipidus).
Oxytocin
- Synthesized primarily in the paraventricular nuclei of the hypothalamus
- Amino acid sequence: Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-GlyNH₂
- Functions: Stimulates uterine contractions during labor; promotes milk ejection (let-down reflex) during breastfeeding.
The two hormones differ by only two amino acids, which explains their partial functional overlap. — Guyton and Hall: Textbook of Medical Physiology
1.5 Pharmacology of Pituitary-Related Drugs
A. Growth Hormone (GH) and Related Drugs
Physiology: GH (somatotropin) promotes growth primarily by stimulating the liver to produce Insulin-like Growth Factor-1 (IGF-1). Deficiency in childhood leads to dwarfism; excess leads to gigantism (pre-puberty) or acromegaly (post-puberty).
| Drug | Class | Indication | Pharmacology |
|---|---|---|---|
| Somatropin | Recombinant GH | GH deficiency in children and adults | Daily SC injection; stimulates growth via IGF-1 stimulation |
| Somapacitan | Long-acting GH analogue | Adult GH deficiency | Weekly SC injection |
| Mecasermin (IGF-1) | Recombinant IGF-1 | Children with GH receptor mutations | Used when GH receptors are non-functional; adverse effects include hypoglycemia |
| Octreotide | Somatostatin analogue | Acromegaly, carcinoid syndrome | Inhibits GH secretion by mimicking somatostatin |
| Pegvisomant | GH receptor antagonist | Acromegaly | Blocks GH receptor → normalizes IGF-1 |
| Tesamorelin | GHRH analogue | HIV-associated lipodystrophy | Reduces visceral fat by stimulating GH release |
| Macimorelin | Ghrelin mimetic | Diagnosis of adult GH deficiency | Orally available; stimulates GH secretion for testing |
— Goodman & Gilman's: The Pharmacological Basis of Therapeutics
B. Prolactin and Dopamine Agonists
Dopamine is the primary inhibitor of prolactin secretion. It is released from hypothalamic neurons into the hypophyseal portal system and acts on D2 receptors on lactotrophs to suppress prolactin secretion.
Hyperprolactinemia is the most common pituitary hormone disorder. It causes galactorrhea, amenorrhea, and infertility in women; and sexual dysfunction in men.
| Drug | Class | Indication | Mechanism |
|---|---|---|---|
| Bromocriptine | Ergot-derived D2 agonist | Hyperprolactinemia, Parkinson's disease | Activates D2 receptors on lactotrophs → ↓ prolactin secretion |
| Cabergoline | Ergot-derived D2 agonist (preferred) | Hyperprolactinemia | Higher D2 affinity, longer half-life than bromocriptine; once or twice weekly dosing |
Both drugs have high affinity for D2 receptors and lower affinity for D1, 5-HT, and adrenergic receptors. The risk of valvular heart disease associated with ergot therapy is not significant at the low doses used for hyperprolactinemia. — Goodman & Gilman's: The Pharmacological Basis of Therapeutics
C. Gonadotropins and GnRH Analogues
| Drug | Class | Indication | Mechanism |
|---|---|---|---|
| Leuprolide, Goserelin, Triptorelin | GnRH agonist analogues | Prostate/breast cancer, endometriosis, precocious puberty | Continuous stimulation of GnRH receptors → receptor downregulation → ↓ FSH/LH → ↓ sex hormones |
| Cetrorelix, Ganirelix | GnRH antagonists | Controlled ovarian stimulation (IVF) | Competitive blockade of GnRH receptors → immediate suppression |
| Human Chorionic Gonadotropin (hCG) | LH mimic | Infertility, cryptorchidism | Activates LH receptors → induces ovulation or testosterone production |
Key Pharmacy Point: GnRH agonists paradoxically cause initial hormone surge ("flare") followed by prolonged suppression. GnRH antagonists produce immediate suppression without a flare.
D. ADH (Vasopressin) and Related Drugs
| Drug | Indication | Notes |
|---|---|---|
| Desmopressin (DDAVP) | Central diabetes insipidus, nocturnal enuresis, von Willebrand disease | Synthetic ADH analogue; no vasopressor activity at therapeutic doses |
| Vasopressin | Vasodilatory shock (septic shock), GI hemorrhage | Vasoconstriction via V1 receptors |
| Tolvaptan, Conivaptan | Hyponatremia (SIADH), hypovolemia | V2 receptor antagonists (vaptans); cause aquaresis |
E. Oxytocin and Tocolytics
| Drug | Indication | Notes |
|---|---|---|
| Oxytocin (Pitocin) | Induction/augmentation of labor, postpartum hemorrhage | IV infusion; may cause hypotension and reflex tachycardia; hyperstimulation of uterus must be avoided |
| Atosiban | Tocolysis (preterm labor) | Oxytocin receptor antagonist; widely used in Europe; not FDA-approved in US |
1.6 Disorders of the Pituitary Gland (Summary for Context)
| Disorder | Cause | Consequence |
|---|---|---|
| Gigantism | Excess GH before epiphyseal closure | Excessive linear growth |
| Acromegaly | Excess GH after epiphyseal closure | Enlarged hands, feet, jaw; organomegaly |
| Hyperprolactinemia | Prolactinoma or dopamine antagonist drugs | Galactorrhea, amenorrhea, infertility |
| Central Diabetes Insipidus | ADH deficiency | Polyuria, polydipsia, dilute urine |
| SIADH | Excess ADH | Hyponatremia, fluid retention |
| Panhypopituitarism | Pituitary tumor, surgery, Sheehan's syndrome | Deficiency of all anterior pituitary hormones |
PART 2: THE THYROID GLAND
2.1 Anatomy and Structure
The thyroid gland consists of two lateral lobes connected by a thin isthmus, located below and anterior to the larynx in the neck. It develops embryologically as an evagination of the pharyngeal epithelium that descends from the foramen cecum at the base of the tongue to its final position in the anterior neck. This descent pathway explains why ectopic thyroid tissue can be found at the base of the tongue (lingual thyroid) or in the anterior neck.
Histology: The gland is divided by thin fibrous septa into lobules, each composed of 20–40 colloid-filled follicles lined by a cuboidal to low columnar epithelium. The follicular lumen is filled with thyroglobulin-rich colloid. Parafollicular C cells (between follicles) secrete calcitonin.
— Robbins, Cotran & Kumar: Pathologic Basis of Disease
2.2 Thyroid Hormone Synthesis
Thyroid hormone synthesis is a multi-step process:
Step 1 — Iodide Uptake: Iodide (I⁻) is actively transported into follicular cells from the blood by the sodium-iodide symporter (NIS) on the basolateral membrane.
Step 2 — Organification: Iodide is oxidized to iodine by thyroid peroxidase (TPO) and incorporated into tyrosyl residues of thyroglobulin (stored as monoiodotyrosine [MIT] and diiodotyrosine [DIT]).
Step 3 — Coupling: TPO also catalyzes the coupling of:
- DIT + DIT → Thyroxine (T4)
- MIT + DIT → Triiodothyronine (T3)
Step 4 — Storage and Release: Iodinated thyroglobulin is stored in the follicular colloid. In response to TSH, it is endocytosed, hydrolyzed by lysosomal proteases, and T4/T3 are released into the bloodstream.
Step 5 — Peripheral Conversion: In target tissues, deiodinase enzymes convert T4 (prohormone) to the more active T3, which binds thyroid hormone nuclear receptors (TR-α and TR-β) with ~10-fold greater affinity than T4.
2.3 Regulation: Hypothalamic–Pituitary–Thyroid Axis
The thyroid axis operates via a classic negative feedback loop:
- Hypothalamus secretes TRH → stimulates anterior pituitary thyrotrophs
- Anterior pituitary secretes TSH → binds TSH receptors on thyroid follicular cells → activates Gs protein → ↑ cAMP → stimulates thyroid hormone synthesis and release
- Circulating T3/T4 feed back to suppress both TRH and TSH secretion
- Decreased T3/T4 → increases TRH/TSH → restores thyroid hormone levels
— Robbins, Cotran & Kumar: Pathologic Basis of Disease
2.4 Physiological Effects of Thyroid Hormones
Thyroid hormones exert widespread effects:
| System | Effect |
|---|---|
| Metabolism | ↑ Basal metabolic rate; stimulates carbohydrate and lipid catabolism; ↑ protein synthesis |
| Cardiovascular | ↑ Heart rate, cardiac output, and contractility |
| Nervous System | Essential for fetal and neonatal brain development; maintains cognition and reflexes in adults |
| Skeletal | Essential for normal bone development and linear growth |
| GI | ↑ Gut motility |
| Temperature | Thermogenesis; maintenance of body temperature |
Key Pharmacy Point: Most circulating T4 and T3 are bound to carrier proteins (thyroxine-binding globulin [TBG], transthyretin, albumin). Only free (unbound) hormone is biologically active. TBG levels (elevated in pregnancy or with estrogen use) affect total T4/T3 but NOT free hormone levels.
2.5 Thyroid Disorders
A. Hypothyroidism
Definition: Insufficient thyroid hormone production.
Causes:
- Hashimoto's thyroiditis (most common in adults) — autoimmune destruction of the thyroid
- Post-treatment for hyperthyroidism (radioiodine or surgery)
- Iodine deficiency (most common worldwide)
- Congenital hypothyroidism (cretinism)
- Drug-induced (lithium, amiodarone, interferon)
Clinical Features: Fatigue, weight gain, cold intolerance, constipation, dry skin, bradycardia, depression, myxedema, goiter. In neonates: intellectual disability, growth failure if untreated.
B. Hyperthyroidism (Thyrotoxicosis)
Definition: Excess thyroid hormone.
Causes:
- Graves' disease (most common) — TSH receptor-stimulating autoantibodies (TSI)
- Toxic multinodular goiter
- Toxic adenoma
- Excess iodine (Jod-Basedow effect)
Clinical Features: Weight loss, heat intolerance, palpitations, tremor, anxiety, exophthalmos (in Graves'), tachycardia, diarrhea, sweating, goiter.
2.6 Pharmacology of Thyroid and Antithyroid Drugs
A. Thyroid Hormone Replacement
| Drug | Class | Indication | Pharmacology |
|---|---|---|---|
| Levothyroxine (T4) | Synthetic T4 | Hypothyroidism, goiter suppression | Drug of choice; long half-life (~7 days); converted peripherally to active T3; taken on empty stomach |
| Liothyronine (T3) | Synthetic T3 | Myxedema coma, short-term suppression testing | Faster onset but shorter half-life than T4; more cardiac effects |
| Liotrix (T4 + T3 combination) | Combined | Rarely used | Fixed T4:T3 ratio |
Key Drug Interactions Affecting Levothyroxine Dosage:
Drugs that INCREASE levothyroxine requirements (↓ absorption or ↑ metabolism):
- Antacids (aluminum-containing), PPIs, sucralfate
- Calcium carbonate, iron salts
- Bile acid sequestrants (cholestyramine, colestipol)
- Rifampin, carbamazepine, phenytoin, phenobarbital (CYP3A4 induction → ↑ T4 metabolism)
- Estrogen and pregnancy (↑ TBG → ↑ dosage need)
Drugs that DECREASE T4 → T3 conversion:
- Amiodarone, glucocorticoids, beta-blockers
— Goodman & Gilman's: The Pharmacological Basis of Therapeutics
B. Antithyroid Drugs (Treatment of Hyperthyroidism)
There are four main categories of thyroid inhibitors:
Category 1 — Thionamides (Thioureylenes)
These are the mainstay of medical treatment for hyperthyroidism.
Mechanism of Action:
- Inhibit thyroid peroxidase (TPO) → block organification of iodide (incorporation into thyroglobulin)
- Block coupling of iodotyrosine residues to form T3/T4
- Propylthiouracil (PTU) only: additionally inhibits peripheral deiodination of T4 → T3 (this makes PTU preferred in thyroid storm)
| Drug | Dosing Frequency | Plasma t½ | Protein Binding | Special Features |
|---|---|---|---|---|
| Propylthiouracil (PTU) | 1–4 times daily | ~75 min | ~75% | Preferred in thyroid storm, 1st trimester of pregnancy; inhibits peripheral T4→T3 conversion |
| Methimazole | Once or twice daily | ~4–6 h | None | Preferred agent in most cases; once-daily dosing improves adherence; avoid in 1st trimester |
| Carbimazole | — | Prodrug | — | Metabolized to methimazole after absorption; used in Europe |
Adverse Effects of Thionamides:
- Agranulocytosis (rare but serious — warn patients to report fever/sore throat immediately)
- Hepatotoxicity (PTU > methimazole)
- Rash, urticaria
- PTU preferred in pregnancy (1st trimester) due to teratogenicity concerns with methimazole (choanal atresia, aplasia cutis)
— Goodman & Gilman's: The Pharmacological Basis of Therapeutics
Category 2 — Ionic Inhibitors
These compete with iodide for uptake into thyroid via the NIS transporter.
| Agent | Use |
|---|---|
| Perchlorate | Rarely used; treats amiodarone-induced hyperthyroidism |
| Thiocyanate | Mainly a goitrogen (from dietary sources, e.g., cabbage) |
Category 3 — Iodine at High Concentrations (Wolff-Chaikoff Effect)
Large doses of iodine paradoxically suppress thyroid hormone synthesis and release:
- Used pre-operatively before thyroid surgery (Lugol's iodine / potassium iodide solution)
- Reduces vascularity and firmness of the gland
- Rapid onset (days) — useful in thyroid storm preparation
- Effect is temporary (escape from the Wolff-Chaikoff effect occurs in 1–2 weeks)
Category 4 — Radioactive Iodine (¹³¹I)
- Mechanism: Taken up by thyroid follicular cells; emits beta particles → destroys thyroid tissue
- Indication: Graves' disease (definitive treatment), toxic nodular goiter
- Contraindications: Pregnancy, breastfeeding
- Outcome: Often leads to permanent hypothyroidism → requires lifelong levothyroxine
C. Adjunct Drugs in Hyperthyroidism
| Drug | Class | Role |
|---|---|---|
| Propranolol, Atenolol | Beta-blockers | Rapid control of palpitations, tremor, anxiety, tachycardia; do not reduce T4/T3 production |
| Propranolol | Non-selective beta-blocker | Also inhibits peripheral T4 → T3 conversion |
| Diltiazem | Calcium channel blocker | Alternative if beta-blockers are contraindicated |
| Glucocorticoids | e.g., Dexamethasone | Reduce T4 → T3 conversion; used in thyroid storm |
D. Summary Table: Drugs Used in Thyroid Storm
Thyroid storm is a life-threatening emergency (extreme hyperthyroidism + systemic decompensation). Treatment combines:
- PTU (first-line thionamide — blocks synthesis AND peripheral conversion)
- High-dose iodine (given 1 hour AFTER PTU to avoid fueling hormone synthesis)
- Beta-blocker (propranolol — controls cardiovascular symptoms)
- Glucocorticoids (↓ T4 → T3 conversion, ↓ adrenal insufficiency risk)
- Supportive care (fluids, antipyretics — avoid aspirin as it displaces thyroid hormone from TBG)
2.7 Investigational and Emerging Therapies
- Resmetirom — TRβ-selective thyroid hormone analogue under investigation for non-alcoholic steatohepatitis (NASH); exploits liver-specific TRβ activity without cardiac side effects
- Triac — T3 metabolite; being studied for Allan-Herndon-Dudley syndrome (MCT8 deficiency, a thyroid hormone transporter defect)
— Goodman & Gilman's: The Pharmacological Basis of Therapeutics
COMPARATIVE SUMMARY: PITUITARY vs. THYROID GLAND
| Feature | Pituitary Gland | Thyroid Gland |
|---|---|---|
| Location | Base of brain, sella turcica | Anterior neck, below larynx |
| Lobes | Anterior (adenohypophysis) + Posterior (neurohypophysis) | Two lateral lobes + isthmus |
| Hormones | GH, PRL, ACTH, TSH, FSH, LH, ADH, Oxytocin | T3, T4, Calcitonin |
| Regulated by | Hypothalamic releasing/inhibiting hormones | TSH from anterior pituitary |
| Key drug target | D2 receptors (dopamine agonists for prolactinoma) | Thyroid peroxidase (thionamides) |
| Primary excess disorder | Acromegaly, Cushing's, Hyperprolactinemia | Graves' disease (hyperthyroidism) |
| Primary deficiency disorder | Panhypopituitarism, Central DI | Hypothyroidism (Hashimoto's) |
| Replacement therapy | Somatropin (GH), Desmopressin (ADH) | Levothyroxine (T4) |
PRACTICE QUESTIONS
Q1. A patient with Graves' disease is prescribed propylthiouracil (PTU). What is its primary mechanism of action, and what makes it preferable to methimazole in thyroid storm?
Answer: PTU inhibits thyroid peroxidase, blocking organification and coupling of iodotyrosines, and additionally inhibits peripheral conversion of T4 to active T3 (deiodinase inhibition). Methimazole lacks this second action, making PTU more effective in rapidly reducing circulating active hormone during thyroid storm.
Q2. A woman on levothyroxine for hypothyroidism is started on cholestyramine for hypercholesterolemia. What interaction should the pharmacist counsel her on?
Answer: Cholestyramine (a bile acid sequestrant) binds levothyroxine in the gut and reduces its absorption, potentially causing a return of hypothyroid symptoms. Levothyroxine should be taken at least 4–6 hours apart from cholestyramine. TSH levels should be rechecked after initiating the new drug.
Q3. A pituitary tumor is secreting excess prolactin. What is the drug of choice and its mechanism?
Answer: Cabergoline (preferred) or bromocriptine. Both are dopamine D2 receptor agonists. Dopamine is the endogenous inhibitor of prolactin secretion via the tuberoinfundibular pathway. These drugs mimic dopamine, activate D2 receptors on lactotrophs, and suppress prolactin secretion. Cabergoline is preferred due to its longer half-life and fewer side effects.
Q4. What is the Wolff-Chaikoff effect and what is its clinical application?
Answer: The Wolff-Chaikoff effect is the paradoxical inhibition of thyroid hormone synthesis and release by high concentrations of iodide. Clinically, it is used preoperatively (Lugol's iodine) to reduce thyroid vascularity and hormone release before thyroid surgery, and in thyroid storm management. The effect is transient and the thyroid "escapes" in 1–2 weeks.
REFERENCES
- Robbins, S.L., Cotran, R.S., Kumar, V. Pathologic Basis of Disease. Elsevier. (Pituitary Gland: p. 971; Thyroid Gland: p. 995)
- Brunton, L.L. (Ed.). Goodman & Gilman's: The Pharmacological Basis of Therapeutics. McGraw-Hill. (Pituitary-related drugs; Antithyroid drugs: Chapter 47)
- Hall, J.E. Guyton and Hall Textbook of Medical Physiology. Elsevier. (Posterior pituitary hormones: Chapter 76)
---The assignment is complete. Here's a quick overview of what's covered:
What's included:
Part 1 — Pituitary Gland
- Anatomy (sella turcica, two lobes, histology with acidophils/basophils/chromophobes)
- Six anterior pituitary cell types and their hormones
- Hypothalamic-pituitary control (releasing/inhibiting hormones)
- Posterior pituitary: ADH (vasopressin) and oxytocin — structure, synthesis, functions
- Pharmacology: GH drugs (somatropin, octreotide, pegvisomant), dopamine agonists for prolactinoma (bromocriptine, cabergoline), GnRH analogues, vasopressin analogues (desmopressin, tolvaptan), oxytocin
Part 2 — Thyroid Gland
- Anatomy and embryological development
- 5-step thyroid hormone synthesis pathway (NIS, TPO, organification, coupling, peripheral conversion)
- HPT axis and negative feedback
- Physiological effects of T3/T4
- Hypothyroidism vs. hyperthyroidism (causes, clinical features)
- Pharmacology: levothyroxine (drug interactions table), antithyroid drugs (PTU vs. methimazole — mechanism, ADME, comparison), iodine therapies, radioactive iodine, adjuncts (beta-blockers, glucocorticoids)
- Thyroid storm management protocol
Bonus: Comparative summary table, 4 practice Q&A, and references to Robbins, Goodman & Gilman, and Guyton.
This is a shared conversation. Sign in to Orris to start your own chat.